enGene Holdings Inc. files 10-K Annual Report with SEC

EnGene Holdings Inc., a biotechnology company focused on developing novel gene therapies, has submitted its 10-K Annual Report to the SEC. This filing, dated October 31, 2024, provides a comprehensive overview of the company’s financial performance, business operations, and risks for the fiscal year ending on that date. The submission includes various exhibits, such as contracts and agreements, which offer further insight into EnGene’s strategic partnerships and potential growth opportunities.

Attachments:
1. Document: 10-K Annual Report
2. Document: EX-10.32
3. Document: EX-10.33

Company Website: Not Available

Original Filing: SEC Accession No. 0000950170-24-138472